Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Bad
|
New words:
AbbVie, accredited, ADME, AGP, API, ATM, Atrophy, BAT, Biden, Black, blurry, bottle, bowel, Brexit, Brimochol, brow, bundled, byTreatment, Canadian, cap, capping, CDMO, CECL, CMC, condensed, CRL, DMF, dry, economy, eighteen, element, encourage, Eotaxin, exit, fabric, Faricimab, fellow, filer, filled, GA, GMP, guanylate, ID, importantly, inconsequential, InflammX, inflationary, inline, JonesTrading, kallikrein, Kingdom, lab, LDP, legacy, Lenz, loan, longevity, macroeconomic, manifesting, Master, Mechanistic, MHRA, mITT, NaN, nightly, nonstatutory, overuse, oxidative, Paper, Paremyd, PDUFA, penny, PKI, POS, PP, predominant, Processa, provisional, RDO, remeasurement, Rescue, Rezolute, Russia, RVO, school, Session, sparse, steady, tester, true, tunability, tunable, twelve, UK, Ukraine, unified, upward, Vabysmo, vega, vertigo, virtual, visibility, vivo, Vuity, VuityTM, Xiflam, younger
Filing tables
Filing exhibits
Related press release
OCUP similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-252715) and Form S-8 (No. 333-254923, 333-249978, 333-217627, 333-189240, and 333-129294) of Ocuphire Pharma, Inc., of our report dated March 24, 2022, relating to the consolidated financial statements of Ocuphire Pharma, Inc., included in this Annual Report (Form 10-K) of Ocuphire Pharma, Inc. for the year ended December 31, 2021.
/s/ Ernst & Young LLP
Detroit, MI
March 24, 2022